Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease
Atypical hemolytic uraemic syndrome is caused by defects in the regulating factors in the alternative pathway of the complement system. Triggering can cause an uncontrolled complement activation with endothelial damage and thrombotic micro-angiopathy, especially in the kidneys. This can result in endstage renal failure. Complement activation during hemodialysis has been described as a result of contact between blood and the dialysis membrane. Our hypothesis is that patients with atypical hemolytic uraemic syndrome have a stronger complement activation during hemodialysis than patients with another underlying kidney disease. This could be a reason to treat patients with endstage renal failure due to atypical hemolytic uraemic syndrome preferentially with peritoneal dialysis instead of hemodialysis.
Atypical Hemolytic Uraemic Syndrome.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease.|
- C3a-des-Arg measuring (as a marker of activation). [ Time Frame: at time 0, at 15 minutes, at 60 minutes and at 180 minutes ] [ Designated as safety issue: No ]
- white blood cell count [ Time Frame: before and after 15 minutes of hemodialysis ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||August 2009|
|Estimated Study Completion Date:||July 2015|
|Estimated Primary Completion Date:||July 2015 (Final data collection date for primary outcome measure)|
patients with endstage renal failure due to atypical uraemic syndrome treated with hemodialysis.
patiënts with endstage renal failure due to a non complement consuming nephropathy treated with hemodialysis.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00930423
|Contact: Rogier Caluwé, MDemail@example.com|
|University Hospital Ghent||Recruiting|
|Ghent, Belgium, 9000|
|Contact: Rogier Caluwé, MD firstname.lastname@example.org|
|Principal Investigator: Raymond Vanholder, MD, PhD|
|Sub-Investigator: Rogier Caluwé, MD|
|Principal Investigator:||Raymond Vanholder, MD, PhD||University Hospital, Ghent|